Efficacy of quadruple therapy combined with probiotics for helicobacter pylori-positive erosive gastritis / 中国基层医药

ABSTRACT

Objective:To investigate the clinical efficacy of quadruple therapy combined with probiotics for helicobacter pylori-positive erosive gastritis.Methods:A total of 350 patients with helicobacter pylori-positive erosive gastritis who received treatment in Jinan Seventh People's Hospital from January 2020 to January 2021 were included in this study. They were randomly assigned to receive a quadruple therapy (clarithromycin, ribavirin, amoxicillin and rabeprazole) alone (control group, n = 175) or in combination with probiotics (observation group, n = 175) for 2 weeks. Clinical efficacy was compared between the two groups. Results:Total response rate was 90.86% (150/175) in the observation group, which was significantly higher than that in the control group [72.57% (127/175), χ 2 = 19.58, P < 0.001]. After treatment, gastrointestinal microbiota were improved in both groups, but the improvements were greater in the observation group than in the control group ( t = 15.14, 14.30, 17.37, all P < 0.001). At 3 and 6 months after treatment, conversion rates from helicobacter pylori-positive to helicobacter pylori-negative in the observation group were 72.57% (127/175) and 95.43% (167/175) respectively, which were significantly higher than 50.29% (88/175) and 79.43% (139/175) in the control group (χ 2 = 18.34, 20.38, both P < 0.001). After treatment, the amplitude of decrease in serum level of gastrin, motilin, tumor necrosis factor-α and interleukin-6 in the observation group were greater than those in the control group ( t = 35.15, 44.91, 16.76, 5.73, all P < 0.001). Conclusion:Quadruple therapy combined with probiotics is highly effective on helicobacter pylori-positive erosive gastritis. The combined therapy can increase conversion rate from helicobacter pylori-positive to helicobacter pylori-negative, improve gastrointestinal function, and greatly inhibit inflammatory reaction.